Drugs / MV-012-968
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04909021 | Jun 2021 → Oct 2023 | respiratory syncytial virus infectious disease | Meissa Vaccines, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04444284 | Jun 2020 → May 2021 | respiratory syncytial virus infectious disease | Meissa Vaccines, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04227210 | Jan → Aug 2020 | respiratory syncytial virus infectious disease | Meissa Vaccines, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04690335 | Dec 2020 → May 2021 | respiratory syncytial virus infectious disease | Meissa Vaccines, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-012-968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04227210 ↗ |
| Modality | Vaccine | “investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV)” NCT04227210 ↗ |
| Route | Intranasal | “Single dose administered intranasally on Day 1” NCT04227210 ↗ |